Loading...
•
Mar 28, 2020
Hologic Q2 2020 Earnings Report
Revenue declined due to Cynosure divestiture, but organic revenue increased, and the company posted positive GAAP and non-GAAP EPS.
Key Takeaways
Hologic's second quarter revenue decreased by 7.6% due to the Cynosure divestiture, but organic revenue increased by 0.5%. The company reported GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.57. Hologic is also introducing a second high-throughput Coronavirus test for its Panther® platform.
Second quarter revenue decreased 7.6% due to Cynosure divestiture, 7.1% in constant currency.
Organic revenue increased 0.5%, 1.1% in constant currency.
Company posted GAAP diluted EPS of $0.36, non-GAAP diluted EPS of $0.57.
Company to introduce second high-throughput Coronavirus test for Panther® Platform.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Hologic expects the COVID-19 pandemic to have a significant negative impact on its future revenue and operating income, especially in the third quarter of fiscal 2020 and withdrew its financial guidance for the second quarter and full year 2020.
Challenges Ahead
- COVID-19 pandemic is expected to have a significant negative impact on future revenue.
- COVID-19 pandemic is expected to have a significant negative impact on operating income.
- The scope and duration of the COVID-19 pandemic are uncertain.
- Financial guidance for the second quarter of fiscal year 2020 was withdrawn.
- Financial guidance for the full year 2020 was withdrawn.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...